<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; a</title>
	<atom:link href="http://www.tapanray.in/tag/a/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Hepatitis C: A Silent, Deadly Disease: Treatment Beyond Reach of Most Indians</title>
		<link>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians</link>
		<comments>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/#comments</comments>
		<pubDate>Mon, 04 Aug 2014 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[cirrhosis]]></category>
		<category><![CDATA[D]]></category>
		<category><![CDATA[E]]></category>
		<category><![CDATA[Egypt]]></category>
		<category><![CDATA[executive]]></category>
		<category><![CDATA[fibrosis]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[HCV]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[hepatocellular carcinoma]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infected]]></category>
		<category><![CDATA[inhibitor]]></category>
		<category><![CDATA[interferon]]></category>
		<category><![CDATA[IOM]]></category>
		<category><![CDATA[John]]></category>
		<category><![CDATA[liver]]></category>
		<category><![CDATA[Martin]]></category>
		<category><![CDATA[Metropolis]]></category>
		<category><![CDATA[NCDC]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pegylated]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[protease]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ribavitin]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5697</guid>
		<description><![CDATA[Every year, July 28 is remembered as the ‘World Hepatitis Day’. In India, this year too, the day had gone by virtually uneventful, for various reasons. This happened despite increasing trend of the disease in the country. Though, there are &#8230; <a href="http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma industry requires striking a right balance between ethical obligations to shareholders and ethical obligations to patients</title>
		<link>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients</link>
		<comments>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/#comments</comments>
		<pubDate>Mon, 24 Sep 2012 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[obligations]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[requires]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=6</guid>
		<description><![CDATA[On September 15, 2012, while delivering his keynote address in a pharmaceutical industry function, Dr. Sam Pitroda, the Chicago based Indian, creator of the telecom revolution in India and the Advisor to the Prime Minister on Public Information, Infrastructure &#38; &#8230; <a href="http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The New Drug Policy of India enters into the final lap of a Marathon Run</title>
		<link>http://www.tapanray.in/the-new-drug-policy-of-india-enters-into-the-final-lap-of-a-marathon-run/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-new-drug-policy-of-india-enters-into-the-final-lap-of-a-marathon-run</link>
		<comments>http://www.tapanray.in/the-new-drug-policy-of-india-enters-into-the-final-lap-of-a-marathon-run/#comments</comments>
		<pubDate>Mon, 21 May 2012 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[enters]]></category>
		<category><![CDATA[final]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[lap]]></category>
		<category><![CDATA[Marathon]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM2011]]></category>
		<category><![CDATA[NPPP2011]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Run]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=91</guid>
		<description><![CDATA[Final working out and thereafter announcement of much awaited and long overdue the new ‘Drug Policy’ of India has now entered into a very interesting stage. This is mainly because of the unique combination of the following three key reasons: &#8230; <a href="http://www.tapanray.in/the-new-drug-policy-of-india-enters-into-the-final-lap-of-a-marathon-run/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-new-drug-policy-of-india-enters-into-the-final-lap-of-a-marathon-run/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The New Drug Policy is languishing in a labyrinth</title>
		<link>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-new-drug-policy-is-languishing-in-a-labyrinth</link>
		<comments>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/#comments</comments>
		<pubDate>Mon, 02 Apr 2012 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DPCO95]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[languishing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM2011]]></category>
		<category><![CDATA[NPPP 2011]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=113</guid>
		<description><![CDATA[Drug Price Control has remained the key feature of all Drug Policies of India, since their inception in early 70’s. Most of these policies continued to remain behind their times consistently, without any exception. That said, the Drug Policy 1994 &#8230; <a href="http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Getting unfolded a global opportunity for India with Biosimilar Drugs</title>
		<link>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 19 Dec 2011 00:20:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Getting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[unfolded]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=159</guid>
		<description><![CDATA[Over a period of time, the trend of a disease treatment process is becoming more targeted and personalized to improve effectiveness of both diagnosis and treatment. Biotechnology being the key driver to this trend, India should not fall out of &#8230; <a href="http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Health being a basic human right, the proposal for ‘Universal Health Coverage’ augurs well for India</title>
		<link>http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india</link>
		<comments>http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[augurs]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[Being]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=162</guid>
		<description><![CDATA[“The right to health is relevant to all States: every State has ratified at least one international human rights treaty recognizing the right to health. Moreover, States have committed themselves to protecting this right through international declarations, domestic legislation and &#8230; <a href="http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>From Cross-Licensing to ‘Patent Pools’ and&#8230; India: Will there be a ground swell?</title>
		<link>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell</link>
		<comments>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/#comments</comments>
		<pubDate>Mon, 23 May 2011 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Cross]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pools]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[swell]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Will]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=254</guid>
		<description><![CDATA[Since many years, the global pharmaceutical industry has been making effective commercial use of cross-licensing, however, by and large, the industry still does not seem to be quite in favor of  &#8216;Patent Pools&#8217; for various reasons. The ‘Patent Pool’, as &#8230; <a href="http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biologic Medicine: Ushers in a different &#8216;Mega Race&#8217; for inorganic growth</title>
		<link>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth</link>
		<comments>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/#comments</comments>
		<pubDate>Mon, 02 May 2011 00:30:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biologicals]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[different]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Race]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Ushers]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=265</guid>
		<description><![CDATA[During the last several years the success of biologics compared to conventional small-molecule drugs to meet the unmet needs of patients, is gradually but surely changing the area of focus of pharmaceutical R&#38;D altogether, making the biotech companies interesting targets &#8230; <a href="http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Limiting FDI in Pharma is a protectionist cry: Does not benefit the common man.</title>
		<link>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man</link>
		<comments>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/#comments</comments>
		<pubDate>Sat, 08 Jan 2011 16:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[automatic]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[cry]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Limiting]]></category>
		<category><![CDATA[man. foreign]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[protectionist]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[route]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=317</guid>
		<description><![CDATA[“Protectionism is harmful” very aptly commented by Mr. Pranab Mukherjee, the Finance Minister of India, just the other day. This was in context of “recent US moves to hike visa fees and clamp down on outsourcing”. While almost at the &#8230; <a href="http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Non-Communicable Diseases (NCD) are hitting the poor even harder, economically: a time to ponder and a time to act</title>
		<link>http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act</link>
		<comments>http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/#comments</comments>
		<pubDate>Mon, 06 Dec 2010 00:30:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Communicable]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economically]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[harder]]></category>
		<category><![CDATA[hitting]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[ponder]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=339</guid>
		<description><![CDATA[November 11, 2010 edition of &#8216;The Lancet&#8217; published an article titled, “Raising the priority of preventing chronic diseases: a political process&#8221;. The article enumerated the following: “Chronic diseases, especially cardiovascular diseases, diabetes, cancer, and chronic obstructive respiratory diseases, are neglected &#8230; <a href="http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
